Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04258644
• Other study ID #: BFH-CamrelizumabCombo4
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 1, 2020
• Est. completion date: February 28, 2023

Study information

• Verified date: February 2020
• Source: Beijing Friendship Hospital
• Contact: Zhongtao Zhang
• Phone: 8618811792819
• Email: zhongtao.z[@]139.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. age:18~70; expected survival>3 months

2. pathologically diagnosed gastric cancer or esophageal-gastric-junction cancer, being predominantly adenocarcinoma

3. no previous treatment of anti-cancer drugs

4. ECOG score 0~2

5. CT/MRI/PET-CT diagnosed as unresectable

6. no disfunction of major organs

7. lab results satisfy the following criteria:

• Hb=90g/L

• WBC=3.5×109/L

• Neutrophil=1.5×109/L

• Plt=100×109/L

• ALT?AST=2.5 upper limit (=5 upper limit for patients with liver metastasis)

• Tbil=1.5 upper limit

• serum creatinine=1.5 upper limit

7.women at child-bearing age must be tested negative within 7 days before inclusion, and must be willing to take contraception measures during treatment and within 12 weeks after last dose of treatment; men must be sterilized or willing to take contraception measures during treatment and within 12 weeks after last dose of treatment 8.willing to join this research with hand-signed written Informed consent 9.good compliance for follow-up

Exclusion Criteria:

1. patients with positive HER-2 test

2. with conditions that affect the absorption of oral drugs, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction

3. allergic to carrizumab for injection, apatinib mesylate, paclitaxel for injection (albumin binding type) and tS-1 or relevant drug excipients; allergic to any other monoclonal antibodies; cannot tolerate radiation toxicity;

4. with active autoimmune disease or autoimmune disease history, such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy); patients with complete remission of childhood asthma and require no intervention can be included, whereas those who need medical intervention with bronchodilator cannot be included

5. with congenital or acquired immune defects, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA = 500 IU / ml), hepatitis C (HCV antibody positive, and HCV-RNA higher than the lower detection limit of the analysis method) or combined hepatitis B and hepatitis C co infection

6. immunosuppressive drugs were used within 14 days before the first use of the study drug, excluding nasal spray and inhaled corticosteroids or systemic steroids in physiological dose (i.e. no more than 10 mg / day of prednisolone or other corticosteroids for equivalent amount);

7. inoculated live attenuated vaccine within 4 weeks before the first administration or during the study period

8. severe infection (requiring intravenous drip of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first administration, or fever> 38.5° C of unknown cause during screening / before the first administration

9. known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation

10. objective evidence indicating previous or concurrent pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation-induced pneumonia, drug-related pneumonia, severe impairment of lung function, etc

11. patients with hypertension that cannot be restored to the normal range (systolic blood pressure = 140 mmHg / diastolic blood pressure = 90 mmHg) after treatment with antihypertensive drugs for 3 months

12. patients with uncontrolled clinical symptoms or diseases of the heart, including but not limited to congestive heart failure (NYHA grade > II); unstable or severe angina; acute myocardial infarction within 6 months; patients with clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention; left ventricular ejection fraction (LVEF) < 50%

13. patients at risk of serious bleeding, including but not limited to severe bleeding (bleeding > 30 ml within 3 months), hemoptysis (bleeding > 5 ml within 4 weeks), and thromboembolism events (within the past 12 months)

14. with symptoms indicating Grade 2+ peripheral neuropathy

15. participating in other clinical trials, or participating in any clinical study for drugs within previous 4 weeks

16. other situations that the researchers regard as not suitable for inclusion.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
Combination therapy of 4 drugs, 21 days for one cycle.

Locations

Country	Name	City	State
China	Beijing Friendship Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	R0 resection rate	proportion of patients for whom radical resection can be achieved	3 years
Secondary	ORR	objective response rate	3 years
Secondary	DFS	disease free survival (period)	3 years
Secondary	3-year DFS	3-year disease free survival (rate)	3 years
Secondary	PFS	progression free survival (period)	3 years
Secondary	OS	overall survival (period)	3 years
Secondary	1-year OS	1-year overall survival (rate)	1 year
Secondary	3-year OS	3-year overall survival (rate)	3 years